Covaxin To Enter Human Trial By AIIMS

All India Institute of Medical Sciences (AIIMS), Delhi will begin human trials on 100 healthy volunteers from next week aged between 18 to 55. Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV). This is India’s first indigenous Covid-19 vaccine.

Bharat Biotech had earlier informed that the Phase 1 clinical trial for Covaxin has been initiated across the country from July 15 onwards. This is a randomised, double-blind, placebo-controlled clinical trial on 375 volunteers.

Around 100 volunteers will be kept under observation for a period of nearly 150 days.